---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-197943"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:21:37.157928+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M

## Summary
- 9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.
- Net proceeds estimated at $56.1M after underwriting discounts and offering expenses.
- Proceeds to fund pre-commercial launch of arimoclomol, OLPRUVA support, and development of celiprolol and KP1077.
- Company believes net proceeds plus existing cash will fund operations through Q1 2026; closing expected Aug 12, 2024.

## SEC filing metadata
- accession: 0001193125-24-197943
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000119312524197943/0001193125-24-197943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000119312524197943/d723355d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-197943
- JSON: https://secwatch.observer/filing/0001193125-24-197943.json
- Plain text: https://secwatch.observer/filing/0001193125-24-197943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.